A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT

A Prospective, Multicenter, Randomized Comparative Evaluation of BuMA Supreme Stent and of Xience Stent in Terms of the Extent of Neointimal Formation at 1 Month and 2 Months Via OCT After Implantation in High Bleeding Risk CAD Patients（PIONEER-II OCT Study）

The objective of this study is a comparative evaluation of BuMA Supreme™ stent and of Xience V/Prime stent in terms of the extent of neointima formation at 1 or 2 months after implanting in relatively high bleeding risk patients with coronary artery disease using OCT.

Study Overview

• Status: Completed
• Conditions: Coronary Artery Disease; Stable Angina Pectoris; Unstable Angina Pectoris
• Intervention / Treatment: Device: BuMA Supreme™ stent; Device: Xience V/Prime stent

Detailed Description

This is a prospective, multicenter, randomized, non-inferiority study, which will enroll a total of 80 subjects from approximately 8 centers. All subjects will be firstly randomly assigned to 1st month OCT (40 pts) or 2nd month OCT group(40 pts). Then both two groups will be randomly assigned to undergoing implantation of BuMA Supreme™ stent (20 pts) or Xience V/Prime stent (20 pts). If non-inferiority was met, superiority test will be planned.

All of the patients be followed up to 2 years. The follow-up visits will be conducted at 1 or 2 months (including QCA/OCT investigation), 3 months, 6 months, 1 and 2 years post percutaneous coronary intervention(PCI),in order to observe the Primary Endpoint and Secondary Endpoints.

• Study Type: Interventional
• Enrollment (Actual): 82
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Beijing
    • BeiJing, Beijing, China, 100853
      • The PLA General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. 18 to 85 years.
2. Evidence of myocardial ischemia without raised troponin (e.g. stable or unstable angina, silent ischemia demonstrated by positive territorial functional study).

3. Any one or more situation listed below can be considered the patient at high bleeding risk by the doctor:

   • Adjunctive oral anticoagulation treatment planned to continue after PCI；
   • Baseline Hb ≥11 g/dl (or anemia requiring TF during the prior 4 weeks)；
   • Any prior intra-cerebral bleed at any time；
   • Any stroke during the past year；
   • Hospital admission for bleeding during the prior 12 months；
   • Non-skin cancer diagnosed or treated ≤ 3 years；
   • Planned daily NSAID (other than aspirin) or steroids for ≥ 30 days after PCI；
   • Planned major surgery (within 1 year)；
   • Renal failure (calculated creatinine clearance ≥ 40 ml/min)；
   • Thrombocytopenia (≥ 100,000/mm3)；
   • Severe chronic liver disease (variceal hemorrhage, ascites, hepatic encephalopathy or jaundice)；

   • Expected non-compliance to prolonged DAPT for other medical (nonfinancial)reasons ；

     • NSAID, Non-steroidal anti-inflammatory drug; TF, blood transfusion.
4. The patient has a planned intervention of up to two de novo lesions, in different epicardial vessels.
5. Lesion(s) must have a visually estimated diameter stenosis of ≥70% and <100%.
6. Reference Vessel Diameter (RVD) must be between 2.5- 4.0mm, and the vessel length must be no more than 40 mm.
7. Written informed consent.
8. The patient and the patient's physician agree to the follow-up visits including angiographic follow-up and OCT controls at 1 or 2 month.

Exclusion Criteria:

1. Evidence of ongoing acute myocardial infarction in ECG prior to procedure.
2. Left ventricular ejection fraction (LVEF) <30%.
3. The patient is a recipient of a heart transplant.
4. Known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, antiplatelet medication specified for use in the study (clopidogrel and ticlopidine), sirolimus or stainless steel, cobalt metal or sensitivity to contrast media, which cannot be adequately pre-medicated.
5. Other medical illness (e.g. skin cancer diagnosed or treated > 3 years, neurological deficiency) or known history of substance abuse (alcohol etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy.
6. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives
7. Chronic total occlusion(TIMI 0), left main lesion, intervention-required three-vessel lesions, branch vessel diameter ≥ 2.5mm and bypass lesion
8. Patients expected not to comply with 1 month DAPT；
9. Compliance with long-term single anti-platelet therapy unlikely；
10. Active bleeding at the time of inclusion；
11. Patients requiring a planned staged PCI procedure more than one week after theindex procedure；
12. Procedure planned to require non-study stents, or stand alone POBA or stand-alone atherectomy；
13. Reference vessel diameter <2.25 - >4.0mm, vessel length >40mm；
14. Cardiogenic shock；
15. Participation in another clinical trial (12 months after index procedure).
16. Those who is not suitable to attend this trial after the evaluation by the doctor.

OCT exclusion criteria

• Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter
• Total occlusion or thrombolysis in myocardial infarction(TIMI) flow 0, prior to wire crossing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: 1st month OCT group implanted BuMA Supreme™ stent; This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.	Device: BuMA Supreme™ stent
ACTIVE_COMPARATOR: 1st month OCT group implanted Xience V/Prime stent; This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.	Device: Xience V/Prime stent
EXPERIMENTAL: 2st month OCT group implanted BuMA Supreme™ stent; This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.	Device: BuMA Supreme™ stent
ACTIVE_COMPARATOR: 2st month OCT group implanted Xience V/Prime stent; This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.	Device: Xience V/Prime stent

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The percentage of the struts' neointimal coverage (%) at 1 or 2 months follow-up by OCT assessment.	1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group	1 or 2 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Neointimal hyperplasia area/volume	1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group	1 or 2 months
Mean/Minimal Stent diameter/area/volume	1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group	1 or 2 months
Mean/Minimal Lumen diameter/area/volume	1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group	1 or 2 months
Mean/maximal thickness of the struts coverage	1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group	1 or 2 months
Incomplete strut apposition	1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group	1 or 2 months
Minimal Lumen Diameter(MLD) and Diameter stenosis percentage(%DS) post procedure and at 3 months	1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group	1 or 2 months
Late Lumen Loss	1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group	1 or 2 month
Binary Restenosis (DS ≥50%)	All measurements will be made of the in-stent, in-segment, proximal and distal stent margins.	1 or 2 months
Acute success rate	It includes the device success,lesion success and procedural success.	up to 7 days
Device-oriented Composite Endpoints and its individual components	Device-oriented Composite Endpoint (DoCE) is defined as cardiac death, Myocardial Infarction(MI) not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization.	1 or 2, 3, 6 months, 1 year, 2 years
Stent thrombosis according to the ARC definitions	Definite and probable stent thrombosis during acute, subacute, later and very late phase.	1 or 2, 3, 6 months, 1 year, 2 years
bleeding events		1 or 2, 3, 6 months, 1 year, 2 years

Collaborators and Investigators

• Sponsor: Sino Medical Sciences Technology Inc.
• Investigators: Principal Investigator: Yundai Y Chen, Ph.D., The PLA General Hospital

Publications and helpful links

General Publications

• Li B, Jin QH, Chen YD, Wang CQ, Shi B, Su X, Fu GS, Wu YQ, Zhou XC, Yuan ZY. A prospective, multicenter, randomized OCT study of early neointimal condition at first and second months after BuMA Supreme stent versus XIENCE stent implantation in high-bleeding-risk coronary artery disease patients: study protocol for a randomized controlled trial. Trials. 2019 Jun 7;20(1):335. doi: 10.1186/s13063-019-3361-0.

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 15, 2016
• Primary Completion (ACTUAL): May 11, 2017
• Study Completion (ACTUAL): March 3, 2021

Study Registration Dates

• First Submitted: April 18, 2016
• First Submitted That Met QC Criteria: April 18, 2016
• First Posted (ESTIMATE): April 21, 2016

Study Record Updates

• Last Update Posted (ACTUAL): October 13, 2021
• Last Update Submitted That Met QC Criteria: October 11, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Keywords: OCT; neointima formation; BuMA Supreme; Xience V/Prime; HT Supreme
• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Pain; Neurologic Manifestations; Coronary Disease; Chest Pain; Coronary Artery Disease; Angina Pectoris; Angina, Stable; Angina, Unstable
• Other Study ID Numbers: PIONEER-II OCT